0008-0100 : Besponsa .25 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution


NDC0008-0100
Labeler: Wyeth Pharmaceuticals Inc., a Subsidiary of Pfizer Inc.
Product Type: Human Prescription Drug
Drug Name:  Besponsa
Dosage Form: Intravenous Injection, Powder, Lyophilized, for Solution
Application #: BLA761040
Rev. Date: 


NDC Package Codes:

  • 0008-0100-01: 1 VIAL, SINGLE‑DOSE IN 1 CARTON (0008‑0100‑01) > 4 ML IN 1 VIAL, SINGLE‑DOSE

Active Ingredients:

  • Inotuzumab Ozogamicin

Dosage Strength:

  • .25 mg/mL

Pharmaceutical Classes:

  • CD22-directed Immunoconjugate [EPC]
  • CD22-directed Antibody Interactions [MoA]
  • Decreased DNA Integrity [PE]
  • Increased Cellular Death [PE]
  • Immunoconjugates [CS]

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0008-0100 QR Code

< Prev: 0008-0045Next: 0008-0407 >




Notice: The MedsChat® NDC Database compiles publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.


Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 1 September 2017.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA